Takeda Pharmaceutical
TAK
Takeda Pharmaceutical (TAK) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $0.23
- EPS estimate
- $0.17
- EPS surprise
- +33.21%
- Revenue surprise
- +7.83%
- Revenue
- $7.7B
- Revenue estimate
- $7.1B
- Reported
- Jul 30, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Jul 30, 2026 | $0.17 | $0.23 | +33.21% | $7.7B | SEC |
| Q4 2026 | May 13, 2026 | −$0.08 | −$0.05 | +34.75% | $6.9B | SEC |
| Q3 2026 | Jan 29, 2026 | $0.14 | $0.21 | +56.23% | $7.7B | SEC |
| Q2 2026 | Oct 30, 2025 | $0.07 | −$0.03 | −136.29% | $7.2B | SEC |
| Q1 2026 | Jul 30, 2025 | $0.17 | $0.26 | +54.90% | $7.4B | SEC |
| Q4 2025 | May 8, 2025 | −$0.03 | −$0.23 | −718.71% | $7.3B | SEC |
| Q3 2025 | Jan 30, 2025 | $0.09 | $0.05 | −42.67% | $7.4B | SEC |
| Q2 2025 | Oct 31, 2024 | $0.12 | $0.19 | +53.96% | $7.7B | SEC |
| Q1 2025 | Jul 31, 2024 | $0.12 | $0.20 | +65.47% | $8.0B | SEC |
| Q4 2024 | May 9, 2024 | $0.00 | −$0.01 | −339.29% | $6.7B | SEC |
| Q3 2024 | Feb 2, 2024 | $0.10 | $0.23 | +132.55% | $7.5B | SEC |
| Q2 2024 | Oct 26, 2023 | $0.10 | −$0.10 | −207.36% | $7.0B | SEC |
| Q1 2024 | Jul 27, 2023 | $0.14 | $0.20 | +44.50% | $7.5B | SEC |
| Q4 2023 | May 11, 2023 | $0.05 | $0.07 | +46.53% | $7.1B | SEC |
| Q3 2023 | Feb 2, 2023 | $0.28 | $0.29 | +3.14% | $8.4B | SEC |
| Q2 2023 | Oct 27, 2022 | $0.13 | $0.13 | +0.67% | $6.8B | — |
| Q1 2023 | Jul 28, 2022 | $0.24 | $0.25 | +7.03% | $7.3B | — |
| Q4 2022 | May 11, 2022 | $0.06 | −$0.03 | −144.72% | $6.8B | — |
| Q3 2022 | Feb 3, 2022 | $0.22 | $0.16 | −27.21% | $7.8B | — |
| Q2 2022 | Invalid Date | $0.23 | −$0.05 | −120.52% | $7.4B | — |
Quarterly revenue
Frequently asked questions
When did Takeda Pharmaceutical (TAK) last report earnings?
Takeda Pharmaceutical last reported on Jul 30, 2026, covering fiscal Q1 2027.
Did TAK beat earnings estimates?
Yes. Takeda Pharmaceutical reported EPS of $0.23 for Q1 2027 against a $0.17 estimate — a 33.21% beat.
How much revenue did TAK report last quarter?
Takeda Pharmaceutical reported $7.7B in revenue for Q1 2027, against a consensus estimate of $7.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.